Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: Impact of panobinostat, the first-in-class histone deacetylase inhibitor

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 2783-2793

  Redic, Kimberly A ^a   Hough, Shannon M ^b   Price, Erika M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Farydak; HDAC; LBH589; Multiple myeloma; Panobinostat; Relapsed refractory

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CREATININE; DEXAMETHASONE; EVEROLIMUS; IXAZOMIB; LENALIDOMIDE; PANOBINOSTAT; THALIDOMIDE; TRICHOSTATIN A; VORINOSTAT;

ANEMIA; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; DECREASED APPETITE; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FATIGUE; FEVER; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PATIENT CARE; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; ST SEGMENT DEPRESSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 84966783489     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S87962     Document Type: Review

References (55)

1. Jagannath S, Dimopoulos MA, Lonial S. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/ refractory multiple myeloma. Leuk Res. 2010;34(9):1111–1118.
2. Merin NM, Kelly KR. Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel). 2014;8(1):1–20.
3. International Agency for Research on Cancer. Globoscan 2013: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed February 28, 2016.
4. Novartis Pharmaceutical Corporation. FDA Oncologic Drugs Advisory Committee Briefing Document: Panobinostat Capsules; 2014. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ UCM421624.pdf. Accessed November 1, 2015.
5. Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardsom PG. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014;7(1):97–111.
6. Ashjian E, Redic K. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. J Oncol Pharm Pract. 2016;22(2):289–302.
7. Libby E, Garcia D, Quintana D, et al. Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups. Leuk Lymphoma. 2014;55(12):2850–2857.
8. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 2; 2016. Available from: http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed December 11, 2015.
9. Kumar DK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79(7):867–874.
10. Moreau P. The future of therapy for relapsed/refractory multiple myeloma: Emerging agents and novel treatment strategies. Semin Hematol. 2012;49 Suppl 1:S33–S46.
11. Kaufman JL, Fabre C, Lonial S, Richardson PG. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clin Lymphoma Myeloma Leuk. 2013;13(4):370–376.
12. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26(37):5420–5432.
13. Pearl LH, Prodormou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem. 2006;75:271–294.
14. Rosato RR, Alemnara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003;63(13): 3637–3645.
15. Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A. 2006;103(42): 15540–15545.
16. Cea M, Cagnetta A, Gobbi M, et al. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des. 2013;19(4):734–744.
17. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102(24): 8567–8572.
18. Felsenfield G, Groudine M. Controlling the double helix. Nature. 2003; 421(6921):448–453.
19. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer. 2004; 112(1):26–32.
20. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mole Cancer Ther. 2011;10(11): 2034–2042.
21. Adams, J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003;29(Suppl 1):3–9.
22. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-Cell lymphoma. Clin Cancer Res. 2008;14(14):4500–4510.
23. Mitsiades N, Mitsaides CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003;101(10):4055–4062.
24. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin acetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108(10):3441–3449.
25. Farydak (panobinostat capsules) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
26. DeAngelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27(8):1628–1636.
27. Wolf JL, Siegel D, Goldschmidt H, et al. A phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53(9):1820–1823.
28. Ocio EM, Vilanova D, Atadja P, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010;95(5):794–803.
29. San-Miguel JF, Richardson PG, Gunther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31(29):3696–3703.
30. Garnock-Jones KP. Panobinostat: first global approval. Drugs. 2015; 75:695–704.
31. San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicenter, randomized, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–1206.
32. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013; 122(14):2331–2337.
33. San-Miguel JF, Hungria VT, Yoon SS, et al. Efficacy and safety based on duration of treatment of panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma in the Phase 3 Panorama 1 study. Blood. 2014;124(21): 4742.
34. San-Miguel JF, Hungria VT, Yoon SS, et al. Final analysis of overall survival from the phase 3 Panorama 1 trial of panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. Poster 3026, Session 653; presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 2015; Orlando, FL.
35. San-Miguel JF, Hungria VT, Yoon SS, et al. Analysis of outcomes based on response in patients with relapsed or relapsed and refractory multiple myeloma treated with panobinostat or placebo in combination with bortezomib and dexamethasone in the Panorama 1 trial: updated analysis based on prior treatment. Poster 4230, Session 653; presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 2015; Orlando, FL.
36. Reu FJ, Valent J, Malek E, et al. A phase I study of ixazomib in combination with panobinostat and dexamethasone in patients with relapsed or refractory multiple myeloma. Poster 4221, Session 653; presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 2015; Orlando, FL.
37. Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM). Available from: https://clinicaltrials.gov/ct2/show/ NCT01301807?term=NCT01301807&rank=1. Accessed December 11, 2015.
38. Kaufman JL, Zimmerman T, Rosenbaum CA, et al. Phase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: a Multiple Myeloma Research Consortium (MMRC) clinical trial. Blood. 2014;124(21):32.
39. Berdeja JG, Hart LL, Mace JR, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 2015;100(5):670–676.
40. Berdeja JG, Gregory TB, Faber EA, et al. A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM): comparison of two expansion cohorts. Poster 1825, Session 653; presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 2015; Orlando, FL.
41. Mateos M, Spencer A, Taylor K, et al. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (pts) with relapsed (rel) or Rel and refractory (ref) multiple myeloma (MM). J Clin Oncol. 2010;28:15s. Abstr. 8030.
42. Chari A, Cho HJ, Len S, et al. A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Poster 4226, Session 653; presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 2015; Orlando, FL.
43. A Phase I Study of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed and Relapsed/Refractory Multiple Myeloma (PanRVD). Available from: https://clinicaltrials.gov/ct2/show/NCT01965353?term=NCT01965353&rank=1. Accessed December 11, 2015.
44. Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01440582?term=NCT01440582&rank=1. Accessed December 11, 2015.
45. Popat R, Brown S, Flanagan LM, Cavenagh JD. Velcade, thalidomide, dexamethasone and panobinostat (VTD-P) for patients with relapsed and relapsed/refractory myeloma: preliminary results of the Muk-Six phase I/IIa trial. Blood. 2014;124(21):4766.
46. Popat R, Brown SR, Flanagan LM, et al. Bortezomib (Velcade), thalidomide, dexamethasone and panobinostat (VTD-P) is a safe, well tolerated and efficacious regimen for patients with relapsed multiple myeloma: preliminary results of the Muk-Six trial. Poster 1826, Session 653; presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 2015; Orlando, FL.
47. Panobinostat and Everolimus in Treating Patients with Recurrent Multiple Myeloma, non-Hodgkin Lymphoma, or Hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00918333?term=nct00918333&rank=1. Accessed December 11, 2015.
48. Bobrowicz M, Dwojak M, Malenda A, et al. HDAC inhibitors as potential new agents improving the efficacy of monoclonal antibodies. Blood. 2014;124(21):3641.
49. Panobinostat Combined With High-Dose Gemcitabine/Busulfan/ Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT02506959?term=nct02506959&rank=1. Accessed December 11, 2015.
50. Richardson PG, Hungria VTM, Yoon SS. Characterization of the incidence and management of gastrointestinal toxicity in the phase 3 Panorama 1 study of panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2014; 124(21):2120.
51. Hansen VL, Coleman M, Elkins S, et al. An expanded treatment protocol of panobinostat plus bortezomib and dexamethasone in patients with previously treated myeloma. Poster 3027, Session 653; presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 2015; Orlando, FL.
52. Richardson PG, Lee JH, Majer I, Krishna A, Woodman RC. Efficacy of treatments in relapsed or relapsed and refractory multiple myeloma: an indirect treatment comparison. Blood. 2014;124(21):2638.
53. Ruggeri K, Maguire A, Schmitz S, et al. Estimating the relative effectiveness of treatments in relapsed/refractory multiple myeloma through a systematic review and network meta-analysis. Poster 2103, Session 902; presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 2015; Orlando, FL.
54. Radomska H, Canella A, Jessica C, et al. Small RNA deep sequencing highlights the important contribution of MiRNAs in regulating IRF4/c-Myc axis in myeloma development. Poster 1791, Session 651; presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 2015; Orlando, FL.
55. U.S. National Institutes of Health. Clinical Trials Registry. Available from: https://clinicaltrials.gov/. Accessed December 14, 2015.